Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 4/20 | 0.33 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.30 |
| ▸ | CKS1B | P61024 | 1/20 | 0.30 |
| ▸ | SKP1 | P63208 | 1/20 | 0.30 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2276755 | 0.95 | DGAT1 (0.35) | DGAT1NSD2 | |
| SCHEMBL2278551 | 0.93 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL2275312 | 0.90 | TYRO3 (0.33) | DGAT1 | |
| SCHEMBL2277267 | 0.89 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL2279196 | 0.89 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL2278197 | 0.86 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL2272755 | 0.85 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL2277832 | 0.83 | ADORA2A (0.41) | CKS1BSKP1SKP2 | |
| SCHEMBL2278153 | 0.82 | JAK3 (0.35) | DGAT1 | |
| SCHEMBL2278452 | 0.82 | DGAT1 (0.36) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245033-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | DGAT1 4740/4885P2RY14 1304/4885NSD2 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.